2024 VC forecast: Clinical-stage CDMOs likely to have uptick in demand but specialization critical
Clinical-stage CDMOs should expect a rise in demand in 2024 as funding for early-stage biopharma stabilizes and biotechs may shed their in-house manufacturing to save cash, according to three VCs interviewed by Endpoints News.
“If you’re a biotech company and you don’t have to invest in your own manufacturing infrastructure, you are actually going to be in that bucket of companies that is more likely to attract investment,” Eclipse Ventures partner Justin Butler added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
